Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Wendy Parulekar

Showing results (21-30 of 24) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 24 results.
The Lancet. Oncology|March 29, 2023
Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trialChristopher J Sweeney, Andrew J Martin, Martin R Stockler, et al.
The New England Journal of Medicine|June 4, 2019
Enzalutamide with Standard First-Line Therapy in Metastatic Prostate CancerIan D Davis, Andrew J Martin, Martin R Stockler, et al.
European Urology|May 25, 2021
Overall Survival of Men with Metachronous Metastatic Hormone-sensitive Prostate Cancer Treated with Enzalutamide and Androgen Deprivation TherapyChristopher J Sweeney, Andrew J Martin, Martin R Stockler, et al.
Lancet (London, England)|October 1, 2020
Timing of radiotherapy after radical prostatectomy (RADICALS-RT): a randomised, controlled phase 3 trialChristopher C Parker, Noel W Clarke, Adrian D Cook, et al.
Pageof 3

Showing results (21-30 of 24) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 24 results.
The Lancet. Oncology|March 29, 2023
Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trialChristopher J Sweeney, Andrew J Martin, Martin R Stockler, et al.
The New England Journal of Medicine|June 4, 2019
Enzalutamide with Standard First-Line Therapy in Metastatic Prostate CancerIan D Davis, Andrew J Martin, Martin R Stockler, et al.
European Urology|May 25, 2021
Overall Survival of Men with Metachronous Metastatic Hormone-sensitive Prostate Cancer Treated with Enzalutamide and Androgen Deprivation TherapyChristopher J Sweeney, Andrew J Martin, Martin R Stockler, et al.
Lancet (London, England)|October 1, 2020
Timing of radiotherapy after radical prostatectomy (RADICALS-RT): a randomised, controlled phase 3 trialChristopher C Parker, Noel W Clarke, Adrian D Cook, et al.
Pageof 3